



Programs & Services Committee Agenda

City of Newton In City Council

Wednesday, June 21, 2023

7:00 PM

The Programs & Services Committee will hold this meeting as a virtual meeting on Wednesday, June 21, 2023 at 7:00 pm. To view this meeting using Zoom use this link: <https://newtonma-gov.zoom.us/j/87871728496> or call 1-646-558-8656 and use the Meeting ID: 878 7172 8496.

Items Scheduled for Discussion:

- #209-23** **Appointment of James Thompson to the Biosafety Committee**
PRESIDENT ALBRIGHT appointing James Thompson, 11 Byrd Ave, Newton as a member of the Biosafety Committee for a term of office to expire on June 5, 2026. (60 Days: 08/04/2023)
- #145-23** **Requesting a Home Rule Petition**
HER HONOR THE MAYOR requesting a home rule petition and approval for extension of the lease term so that the City can extend its current ground lease with the Newton Community Development Foundation for Warren House for an additional 34 years.
- #231-23** **Request to set Early Voting Hours for the September 12 Preliminary Election (if needed.)**
THE CITY CLERK requesting to set early voting hours for the September 12, 2023 Preliminary Election, if needed, on the following dates, location, and times recommended by the Election Commission: A total of two days; Tuesday September 5, 2023 8:30a-5p and Wednesday September 6, 2023 9a-8p at Newton City Hall, 1000 Commonwealth Avenue, Newton, MA 02459.

The location of this meeting is accessible and reasonable accommodations will be provided to persons with disabilities who require assistance. If you need a reasonable accommodation, please contact the City of Newton's ADA Coordinator, Jini Fairley, at least two business days in advance of the meeting: jfairley@newtonma.gov or (617) 796-1253. The city's TTY/TDD direct line is: 617-796-1089. For the Telecommunications Relay Service (TRS), please dial 711.

#232-23 Request to set Early Voting Hours for the November 7 Municipal Election
THE CITY CLERK requesting to set early voting hours for the November 7, 2023 Municipal Election on the following dates, location, and times recommended by the Election Commission: A total of Five days; Saturday October 28, 2023 11a-5p, Sunday October 29, 2023 11a-5p, Monday October 30, 2023 8:30a-5p, Tuesday October 31, 2023 8:30a-5p, and Wednesday November 1, 2023 8:30a-5p at Newton City Hall, 1000 Commonwealth Avenue, Newton, MA 02459.

#233-23 Request to move Ward 1, Precinct 4 Polling Location
THE CITY CLERK requesting that the Ward 1, Precinct 4 polling location, currently located at the Pellegrini Playground at 11 Hawthorn St be relocated to a new location.

#234-23 Request to move Ward 2, Precinct 1 Polling Location
THE CITY CLERK requesting that the Ward 2, Precinct 1 polling location, currently located at the Albemarle Field House at 250 Albemarle Rd be relocated to Scandinavian Living Center on 206 Waltham St.

#74-23 Requesting a Home Rule Petition
COUNCILORS NORTON, HUMPHREY, MALAKIE, LEARY, BOWMAN, DOWNS, LUCAS, KELLEY, ALBRIGHT, RYAN, LAREDO, WRIGHT, LIPOF, AND MARKIEWICZ requesting a home rule petition so that the City can create an ordinance to prohibit the purchase or application of anti-coagulant rodenticides in Newton.
Programs & Services Held 7-0 on 04/19/23

Referred to Programs & Services and Finance Committees

#155-23 Appropriate \$140,000 to a Parks, Recreation & Culture account
HER HONOR THE MAYOR requesting authorization to appropriate and expend the sum of one hundred forty thousand dollars (\$140,000) from acct # 5503R602-590001 B.A.A Marathon to a Parks, Recreation & Culture Account to fund a "Heartbreak Hill" banner and playground improvements.
Programs & Services Held 6-0 (Councilor Baker Not Voting) on 5/17/23

#370-22 Discussion on Field Maintenance Plan
COUNCILORS KRINTZMAN, BOWMAN, KELLEY, LIPOF, KALIS, LAREDO, CROSSLEY, ALBRIGHT, HUMPHREY, LUCAS, MALAKIE, WRIGHT, MARKIEWIZ, NOEL, DOWNS, LEARY, NORTON, OLIVER AND DANBERG requesting a discussion with the Commissioner of Parks, Recreation and Culture about the maintenance plan for our parks, recreation and culture resources, including recreational fields. This discussion should include an articulation of how additional funds based upon a budget increase and newly collected user group field fees in the upcoming fiscal year will be utilized. Time permitting, the discussion should also include a

description of the capital projects on recreational fields that the department intends to complete in the upcoming fiscal year.

Programs & Services Held 7-0 on 2/16/23

#63-23

Request for a discussion with City Staff regarding a cost-benefit analysis on grass fields

COUNCILORS ALBRIGHT, BAKER, WRIGHT, HUMPHREY AND KELLEY requesting a discussion with the Parks, Recreation, and Culture Department regarding a cost-benefit analysis of grass fields in sufficient quantity to meet Newton's demand for playing time (by user group; Newton school athletic programs, Newton Youth groups, others) vs additional artificial turf fields. This analysis should include the following; quantification of the current demand for playing fields (hours used by field), description of the scheduling system referencing the availability and cost of alternative systems if needed, quantification of field usage as a percentage of field availability, current land acreage and fields now unusable for play as a result of lack of maintenance funds and the additional annual funds needed to use these fields, the resultant playing time available if all grass fields in Newton are usable vs playing time with the addition of artificial turf at specific planned locations, the location of additional potential grass fields, whether existing or new and the impact of these locations on high school sports including added acquisition and/or transportation costs to access fields not located on high school grounds. In addition, such information should take into account the environmental impact of either artificial turf or grass field choices taking into account such things as disposal of turf, chemical contaminants within turf, and pesticides used on grass. This discussion should provide information to guide the Council in its decision for future requests for artificial turf fields.

Referred to Programs & Services and Finance Committees

#453-22

Discussion and Creation of Strategic and Operational Plan for Capital Improvements

COUNCILORS LAREDO, OLIVER, NORTON, LUCAS, WRIGHT, MALAKIE, GENTILE, AND ALBRIGHT requesting a discussion with the Parks, Recreation and Culture Department regarding the creation of a strategic and operational plan for capital improvements to our athletic fields, athletic facilities, and playgrounds. In order to facilitate a productive discussion, ask that we be provided with a single document that lists all of the currently planned capital work (both as set forth in the city's capital improvement plan (CIP) and in the department's annual budgets) prior to the item being discussed. The document should include the following categories: (a) project; (b) anticipated start date; (c) anticipated date of completion; (d) estimated cost; (e) funding source and the anticipated amount from each source; and (f) status of applying for funding.

Programs & Services Held 8-0 on 1/4/23

Respectfully Submitted,

Josh Krintzman, Chair

CITY OF NEWTON

DOCKET REQUEST FORM

RECEIVED

2023 MAY 19 PM 12:04

DEADLINE NOTICE: Council Rules require items to be docketed with the Clerk of the Council NO LATER THAN 7:45 P.M. ON THE MONDAY PRIOR TO A FULL COUNCIL MEETING.

To: Clerk of the City Council

Date: 05/19/2023

From (Docketer): Council President Susan Albright

Address: _____

Phone: _____

E-mail: _____

Additional sponsors: _____

1. Please docket the following item (it will be edited for length if necessary):

PRESIDENT ALBRIGHT appointing James Thompson, 11 Byrd Ave, Newton as a member of the Biosafety Committee for a term of office to expire on June 5, 2026.

2. The purpose and intended outcome of this item is:

- Fact-finding & discussion
- Appropriation, transfer,
- Expenditure, or bond authorization
- Special permit, site plan approval,
- Zone change (public hearing required)

- Ordinance change
- Resolution
- License or renewal
- Appointment confirmation
- Other: _____

3. I recommend that this item be assigned to the following committees:

- | | | |
|---------------------------------------------------------|----------------------------------------|--------------------------------------------|
| <input checked="" type="checkbox"/> Programs & Services | <input type="checkbox"/> Finance | <input type="checkbox"/> Real Property |
| <input type="checkbox"/> Zoning & Planning | <input type="checkbox"/> Public Safety | <input type="checkbox"/> Special Committee |
| <input type="checkbox"/> Public Facilities | <input type="checkbox"/> Land Use | <input type="checkbox"/> No Opinion |

4. This item should be taken up in committee:

Immediately (Emergency only, please). Please state nature of emergency:

- As soon as possible, preferably within a month
- In due course, at discretion of Committee Chair
- When certain materials are made available, as noted in 7 & 8 on reverse
- Following public hearing

PLEASE FILL OUT BOTH SIDES

5. I estimate that consideration of this item will require approximately:

- One half hour or less
- More than one hour
- More than one meeting
- Up to one hour
- An entire meeting
- Extended deliberation by subcommittee

6. The following people should be notified and asked to attend deliberations on this item. (Please check those with whom you have already discussed the issue, especially relevant Department Heads):

City personnel

Citizens (include telephone numbers/email please)

- _____
- _____
- _____
- _____
- _____

- _____
- _____
- _____
- _____
- _____

7. The following background materials and/or drafts should be obtained or prepared by the Clerk's office prior to scheduling this item for discussion:

8. I have or intend to provide additional materials and/or undertake the following research independently prior to scheduling the item for discussion. *

(*Note to docketer: Please provide any additional materials beyond the foregoing to the Clerk's office by 2 p.m. on Friday before the upcoming Committee meeting when the item is scheduled to be discussed so that Councilors have a chance to review all relevant materials before a scheduled discussion.)

Please check the following:

- 9. I would like to discuss this item with the Chairman before any decision is made on how and when to proceed.
- 10. I would like the Clerk's office to contact me to confirm that this item has been docketed. My daytime phone number is:
- 11. I would like the Clerk's office to notify me when the Chairman has scheduled the item for discussion.

Thank you.

/s/Susan Albright
Signature of person docketing the item

[Please retain a copy for your own records]

Application Form

Profile

James

First Name

Middle Initial

Thompson

Last Name

Email Address

11 Byrd Ave

Home Address

Suite or Apt

Newton

City

MA

State

02465

Postal Code

What Ward do you live in?

Ward 3

Primary Phone

Alternate Phone

Photys Therapeutics

Employer

Associate Director - Biochemistry

Job Title

Which Boards would you like to apply for?

Biosafety Committee: Submitted

Interests & Experiences

Please tell us about yourself and why you want to serve.

Why are you interested in serving on a board or commission?

I have been fortunate to make a living pursuing new therapeutics for 25 years. The local growth of life science companies offers benefits regionally and globally. If I can assist in that growth through the biosafety committee I would be pleased to do so.

James E Jed Thompson CV.pdf

Upload a Resume

James E. "Jed" Thompson, Ph.D.
West Newton, MA 02465

SUMMARY

Biochemist with extensive experience in preclinical pharmaceutical research supporting small molecule, therapeutic protein, and antibody modalities. Skilled at leading highly productive project teams to data driven conclusions while managing and developing direct reports.

- Director: Managed laboratories of up to six scientists while personally generating high impact data in the laboratory. Led and mentored direct reports to promotions and multiple publications. Work from team laboratory was incorporated into approved IND applications for DGAT1 inhibitors, one of which reached Phase III clinical testing.
- Project team leader: Proposed three and led seven projects through assay development, high throughput screening and medicinal chemistry optimization. Three projects generated the predicted *in vivo* pharmacology.
- Experimental scientist: Notable accomplishments include a successful platform build, new projects and publications, one of which has been cited over 80 times.

PROFESSIONAL EXPERIENCE

Cyteir Therapeutics, Lexington MA
Associate Director, Biochemistry

2021-2023

Directed Cyteir biochemistry, biophysics and structural biology initiatives. Supervised team of one Senior Scientist, two Associate Scientists and CROs.

- Evaluated HTS hits as starting points for three medicinal chemistry programs; activity data supported lead nomination and patent filings by project team.
- Designed CRO based studies that proved direct binding of Phase II clinical candidate CYT0851 to its membrane spanning target MCT-1.
- Developed methods to identify novel binding sites for test compounds using click chemistry and proteomic analysis.
- Led research team in new target scouting and experimental validation.

LifeMine Therapeutics, Cambridge MA
Principal Scientist, Biochemistry and Biophysics

2018-2021

Laboratory Leader: Designed biochemical assays paired with bespoke controls capable of reporting on active molecules in complex natural product mixtures.

- Biochemical data led to discovery of a novel natural product and first proof of success of the discovery platform.
- Target classes included enzymes and nucleotide binding proteins – 15 assays developed and deployed.
- Established rapid kinetics platform to characterize molecules with novel binding mode. Identified both assay technology and specialized instrumentation to work on a millisecond timescale.
- Supervised a Research Associate and Scientist new to industrial research.

Project Coordinator: Ensured cross-functional communication and addressed resource bottlenecks to meet project timelines.

- Reported results to CEO with recommended action plan.

New Target Scouting: Evaluated human drug targets suggested by genomic search of fungal biosynthetic gene clusters.

- Triaged more than 150 targets based on project feasibility and clinical potential. Presented finalists to CEO for endorsement of two new projects.

Mitobridge Inc., Cambridge MA
Principal Scientist, *In Vitro* Pharmacology

2015-2018

Project team leader – Hit to lead optimization: Led combined team of contracted researchers in India, Mitobridge scientists and consultants to arrive at the most potent and selective ubiquitin specific peptidase 30 inhibitors reported to date.

- Led team to new decision criteria.
- Set cellular assay development priorities and criteria.
- Developed novel activity-based probe assays to report on target engagement in complex samples.
- Proposed a novel target and developed the high throughput screen which identified high potency chemical matter.

Laboratory Leader: Directed experimentation by Ph.D. and M.S. level scientists.

Novartis Institutes for Biomedical Research, Cambridge MA
Investigator III, Department of Cardiovascular and Metabolic Diseases

2006-2015

Laboratory Leader – Bioanalysis (2013-2015): Managed interactions of project teams and a group of six to generate new assays measuring exposure and efficacy of therapeutic proteins, antibodies and pharmacodynamics of low molecular weight compounds.

- Designed an ELISA to measure a recombinant murine protein in mouse plasma. Identified antibody combination that eliminated background from endogenous protein. Assay provided all *in vivo* exposure measurements for an obesity project.
- Identified misleading data for murine hormones from commercial assay kits. Recommended an alternative method that yielded accurate data and eliminated a project team's safety concern.

Laboratory Leader – Biochemistry (2006 to 2013): Pursued low molecular weight compounds as medicines for atherosclerosis, obesity and diabetes.

- Proposed novel approach to an industry consensus atherosclerosis target. The proposal required the endorsement of department vice president and the president of NIBR. Led the project through high throughput screening and medicinal chemistry.
- Led acyltransferase inhibitor discovery project teams (MGAT2 and DGAT2) including direct generation of mass spectrometry-based enzyme assay data which tracked compound potency and led to medicinal chemistry optimization. Pharmacologically active compounds were discovered for both projects.
- Addressed safety concern regarding the metabolic fate of DGAT2 substrates using metabolic tracing by mass spectrometry. Proved that proximal effects of DGAT2 inhibition are benign.
- Contributed data to DGAT1 inhibitor INDs. DGAT1 inhibitor reached phase III.

Merck Research Laboratories, Rahway NJ
Research Fellow, Department of Immunology and Rheumatology
Senior Research Biochemist, Department of Immunology and Rheumatology

1997-2006**2001-2005****1997-2001**

Pursued immunomodulatory protein kinase inhibitors both as a lab leader and project team leader. Developed biochemical assays leading to three medicinal chemistry efforts after high throughput screening. Supervised up to three research associates.

- Developed an enzyme cascade assay that reported on three protein kinases acting on their physiological substrates. Characterized high throughput screening hits leading to an inhibitor selective for one substrate of a protein kinase thought to act on many proteins.
- Discovered an unanticipated chemical transformation leading to an inhibitor of JAK3 protein kinase. The inhibitor was subsequently found to have *in vivo* activity and chemical optimization was initiated. The manuscript describing the inhibitor has been cited over 80 times.

DuPont Stine-Haskell Research Laboratories, Newark DE
Visiting Scientist – sponsor: Douglas B. Jordan

1995-1997

Characterized the interactions of trihydroxynaphthalene reductase of a fungal crop pathogen and a commercial fungicide tricyclazole. Tricyclazole had been reported to bind allosterically to its target.

- Completely revised the mechanism of tricyclazole using steady state and pre-steady state kinetic characterization combined with affinity measurements. The revised mechanism was corroborated by the X-ray diffraction structure of the inhibitor enzyme complex.

EDUCATION

University of Wisconsin at Madison

Ph. D. Biochemistry, advisor Ronald T. Raines (currently Firmenich Professor of Chemistry, MIT) - 1995

University of Michigan – Ann Arbor

B.Sc. Chemistry – 1989

PATENTS

New benzo(h)imidazo(4,5-f)isoquinoline and imidazo(4,5-f)(2,9)phenanthroline derivatives are Janus protein tyrosine kinase inhibitors used for treating e.g. allergies and autoimmune diseases. Cubbon R, Cummings, RT, Goulet JL, Hong X., Sinclair PJ, **Thompson JE**. Patent Number WO200311285 (2003), US Patent #6852727 (2005).

PUBLICATIONS AS CORRESPONDING AUTHOR

Time-resolved Forster resonance energy transfer assays for the binding of nucleotide and protein substrates to p38alpha protein kinase. Zhang WX, Wang R, Wisniewski D, Marcy AI, LoGrasso P, Lisnock JM, Cummings RT, **Thompson JE**. *Anal. Biochem.* (2005) 343(1):76-83.

JAK protein kinase inhibitors. **Thompson JE**, *Drug News Perspect.* (2005) 18(5):305-10. Review.

Mechanism of Janus kinase 3-catalyzed phosphorylation of a Janus kinase 1 activation loop peptide. Wang R, Griffin PR, Small EC, **Thompson JE**. *Arch. Biochem. Biophys.* (2003) 410(1):7-15.

Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor. **Thompson JE**, Cubbon RM, Cummings RT, Wicker LS, Frankshun R, Cunningham BR, Cameron PM, Meinke PT, Liverton N, Weng Y, DeMartino JA. *Bioorg. Med. Chem. Lett.* (2002) 12(8):1219-23.

Detection of ATP competitive protein kinase inhibition by Western blotting. Wang R, **Thompson JE**. *Anal. Biochem.* (2001) 299(1):110-2.

PUBLICATIONS AS FIRST AUTHOR

The second naphthol reductase of fungal melanin biosynthesis in *Magnaporthe grisea*: tetrahydroxynaphthalene reductase. **Thompson JE**, Fahnestock S, Farrall L, Liao DI, Valent B, Jordan DB. *J Biol Chem.* (2000) 275(45):34867-72.

Partition analysis of an enzyme acting concurrently upon two substrates in a continuous multiwavelength assay. **Thompson JE**, Jordan DB. *Anal Biochem.* (1998) 256(1):7-13.

2,3-Dihydro-2,5-dihydroxy-4H-benzopyran-4-one: a nonphysiological substrate for fungal melanin biosynthetic enzymes. **Thompson JE**, Basarab GS, Pierce J, Hodge CN, Jordan DB. *Anal Biochem.* (1998) 256(1):1-6.
Trihydroxynaphthalene reductase from *Magnaporthe grisea*: realization of an active center inhibitor and elucidation of the kinetic mechanism. **Thompson JE**, Basarab GS, Andersson A, Lindqvist Y, Jordan DB. *Biochemistry* (1997) 36(7):1852-60.

Limits to catalysis by Ribonuclease A. **Thompson JE**, Kutateladze TG, Schuster MC, Venegas FD, Messmore JM, Raines RT. *Bioorg. Chem.* (1995) 23(4):471-481.

Energetics of catalysis by ribonucleases: fate of the 2',3'-cyclic phosphodiester intermediate. **Thompson JE**, Venegas FD, Raines RT. *Biochemistry* (1994) 33(23):7408-14.

Value of general Acid-base catalysis to ribonuclease A. **Thompson JE**, Raines RT. *J. Am. Chem. Soc.* (1994) 116(12):5467-8.

PUBLICATIONS AS SECONDARY AUTHOR

Novel and highly selective inhibitors of ubiquitin specific protease inhibitors of ubiquitin specific protease 30 (USP30) accelerate mitophagy. Kluge A, Lagu B, Maiti P, Jaleel M, Webb M, Mallat A, Malhotra J, Srinivas A, **Thompson JE** *Bioorg. Med. Chem. Lett.* (2018) 28(15): 2655-2659.

Discovery of an orally bioavailable benzimidazole diacylglycerol acyltransferase 1 (DGAT1) inhibitor that suppresses body weight gain in diet-induced obese dogs and postprandial triglycerides in humans. Nakajima K, Chatelain R, Clairmont KB, Commerford R, Coppola GM, Daniels T, Forster CJ, Gilmore TA, Gong Y, Jain M, Kanter A, Kwak Y, Li J, Meyers CD, Neubert AD, Szlennik P, Tedesco V, **Thompson J**, Truong D, Yang Q, Hubbard BK, Serrano-Wu MH. *J. Med. Chem.* (2017) 60(11): 4657-4664.

Discovery of diamide compounds as diacylglycerol acyltransferase 1 (DGAT1) inhibitors. Nakajima K, April M, Brewer JT, Daniels T, Forster CJ, Gilmore TA, Jain M, Kanter A, Kwak Y, Li J, McQuire L, Serrano-Wu MH, Streeper R, Szklennik P, **Thompson J**, Wang B. *Bioorg Med Chem Lett.* (2016) 26(4): 1245-8.

Synthetic phospholipids as specific substrates for plasma endothelial lipase. Papillon JP, Pan M, Brousseau ME, Gilchrist MA, Lou C, Singh AK, Stawicki T, **Thompson JE**. *Bioorg Med Chem Lett.* (2016) 26(15): 3514-7.

Synthesis and biological activity of pyridopyridazin-6-one p38 α MAP kinase inhibitors. Part 2 Tynebor RM, Chen MH, Natarajan SR, O'Neill EA, **Thompson JE**, Fitzgerald CE, O'Keefe SJ, Doherty JB. *Bioorg Med Chem Lett.* (2012) 22(18):5979-83.

Synthesis and biological activity of pyridopyridazin-6-one p38 MAP kinase inhibitors. Part 1 Tynebor RM, Chen MH, Natarajan SR, O'Neill EA, **Thompson JE**, Fitzgerald CE, O'Keefe SJ, Doherty JB. *Bioorg Med Chem Lett.* (2011) 21(1):411-6.

Synthesis and biological activity of 2H-quinolizin-2-one based p38 α MAP kinase inhibitors. Tynebor RM, Chen MH, Natarajan SR, O'Neill EA, **Thompson JE**, Fitzgerald CE, O'Keefe SJ, Doherty JB. *Bioorg Med Chem Lett.* (2010) 20(9):2765-9.

Novel 1-(2-aminopyrazin-3-yl)methyl-2-thioureas as potent inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2). Lin S, Lombardo M, Malkani S, Hale JJ, Mills SG, Chapman K, **Thompson JE**, Zhang WX, Wang R, Cubbon RM, O'Neill EA, Luell S, Carballo-Jane E, Yang L. *Bioorg Med Chem Lett.* (2009) 19(12):3238-42.

p38 MAP kinase inhibitors. Part 5: discovery of an orally bio-available and highly efficacious compound based on the 7-amino-naphthyridone scaffold. Natarajan SR, Liu L, Levorse M, **Thompson JE**, O'Neill EA, O'Keefe SJ, Vora KA, Cvetovich R, Chung JY, Carballo-Jane E, Visco DM. *Bioorg Med Chem Lett.* 2006 16(20):5468-71.

p38 MAP kinase inhibitors. Part 6: 2-arylpyridazin-3-ones as templates for inhibitor design. Natarajan SR, Heller ST, Nam K, Singh SB, Scapin G, Patel S, **Thompson JE**, Fitzgerald CE, O'Keefe SJ. *Bioorg Med Chem Lett.* (2006) 16(22):5809-13.

p38 MAP kinase inhibitors. Part 3: SAR on 3,4-dihydropyrimido[4,5-d]pyrimidin-2-ones and 3,4-dihydropyrido[4,3-d]pyrimidin-2-ones. Natarajan SR, Wisnoski DD, **Thompson JE**, O'Neill EA, O'Keefe SJ. *Bioorg Med Chem Lett.* (2006) 16(16):4400-4.

p38 MAP kinase inhibitors: metabolically stabilized piperidine-substituted quinolinones and naphthyridinones. Bao J, Hunt JA, Miao S, Rupprecht KM, Stelmach JE, Liu L, Ruzek RD, Sinclair PJ, Pivnichny JV, Hop CE, Kumar S, Zaller DM, Shoop WL, O'Neill EA, O'Keefe SJ, Thompson CM, Cubbon RM, Wang R, Zhang WX, **Thompson JE**, Doherty JB. *Bioorg. Med. Chem. Lett.* (2006) 16(1):64-8.

p38 Inhibitors: piperidine- and 4-aminopiperidine-substituted naphthyridinones, quinolinones, and dihydroquinazolinones. Hunt JA, Kallashi F, Ruzek RD, Sinclair PJ, Ita I, McCormick SX, Pivnichny JV, Hop CE, Kumar S, Wang Z, O'Keefe SJ, O'Neill EA, Porter G, **Thompson JE**, Woods A, Zaller DM, Doherty JB. *Bioorg. Med. Chem. Lett.* (2003) 13(3):467-70.

Hybrid-designed inhibitors of p38 MAP kinase utilizing N-arylpyridazinones. Colletti SL, Frie JL, Dixon EC, Singh SB, Choi BK, Scapin G, Fitzgerald CE, Kumar S, Nichols EA, O'Keefe SJ, O'Neill EA, Porter G, Samuel K, Schmatz DM, Schwartz CD, Shoop WL, Thompson CM, **Thompson JE**, Wang R, Woods A, Zaller DM, Doherty JB. *J. Med. Chem.* (2003) 46(3):349-52.

A structural account of substrate and inhibitor specificity differences between two naphthol reductases. Liao D-I, **Thompson JE**, Fahnestock S, Valent B, Jordan DB. *Biochemistry* (2001) 40(30), 8696-8704.

His...Asp Catalytic Dyad of Ribonuclease A: Conformational Stability of the Wild-Type, D121N, D121A, and H119A Enzymes. Quirk DJ, Park C, **Thompson JE**, Raines RT. *Biochemistry* (1998) 37 (51), 17958-17964.



Ruthanne Fuller
Mayor

City of Newton, Massachusetts

Office of the Mayor

2023 APR 24 PM 4:44

CITY CLERK
NEWTON, MA. 02459

#145-23

Telephone
(617) 796-1100

Fax
(617) 796-1113

TDD/TTY
(617) 796-1089

Email
rfuller@newtonma.gov

April 24, 2023

Honorable City Council
Newton City Hall
1000 Commonwealth Avenue
Newton, MA 02459

Honorable City Councilors:

I respectfully submit this docket item to this Honorable Council requesting the approval of a home rule petition to allow the City to extend its current ground lease with the Newton Community Development Foundation (NCDF) for Warren House located at 1600 Washington Street.

In 1991 Newton Community Development Foundation (NCDF) purchased the former Warren Junior High School on Washington Street from the City for \$600,000. Subsequently in October of 1992, NCDF entered into a ground lease with the City for 65 years wherein it would operate and manage 59 apartment units in the former school building, 21 of which would be affordable apartments. The terms of the original lease required NCDF to provide the City with a 65 year term lease payment of \$1.5 million, payable in annual installments of \$75,000. The parties also agreed to a provision to defer payment on the annual rent if 50% of the property cash flow in a given year was less than the annual \$75,000 payment and any deferred rent would accrue at 8% simple interest. NCDF has paid all of the City's property taxes since acquiring the building but except for a negligible lease payment of \$3,997 never generated cash flow sufficient to make any further payments on the lease. At present, the outstanding principal rent due to the City is approximately \$1.4 million and the deferred interest is approximately \$2.4 million.

NCDF is looking to both refinance their current mortgage for needed capital improvements and to extend their current ground lease with the City (due to expire in 2056) for an additional 34 years to 2090.

As part of their request, NCDF has offered to provide the following:

1. Upon their refinance, NCDF would pay the City the principal rent balance of \$1.5 million.
2. NCDF would request that the City waive \$1.4 million of the interest amount owed and have NCDF pay a total of \$1 million to the City in equal annual installments of \$38,461 for 26 years, beginning in 2064.
3. In return for the City's forbearance, NCDF would agree to preserve the affordability of the current 21 units (including six where the 50% AMI affordability period has expired) in perpetuity and;
4. Agree to add affordability requirements to make another four (4) units affordable (at 80% AMI) in perpetuity for 25 units in total (42% of all units).

Please see attached a memo from Director of Planning & Development Barney Heath discussing the background and the negotiated solution. Also attached is the draft special act legislation created by the Law Department.

Thank you for your consideration of this matter.

Sincerely,

A handwritten signature in blue ink that reads "Ruthanne Fuller". The signature is written in a cursive style with a large initial "R" and a long horizontal stroke at the end.

Mayor Ruthanne Fuller



Ruthanne Fuller
Mayor

City of Newton, Massachusetts
Department of Planning and Development
1000 Commonwealth Avenue Newton, Massachusetts 02459

#145-23

Telephone
(617) 796-1120
Telefax
(617) 796-1142
TDD/TTY
(617) 796-1089

www.newtonma.gov

Barney Heath
Director

MEMORANDUM

TO: Honorable Mayor Fuller
Jonathan Yeo, Chief Operating Officer

FROM: Barney Heath, Director, Department of Planning and Development

DATE: April 24, 2023

RE: **Docket Request to approve a home rule petition to allow the City to extend its current ground lease with the Newton Community Foundation for Warren House located at 1600 Washington Street.**

CC: Amanda Berman, Director of Community Development & Housing
Lara Kritzer, Community Preservation Act Program Manager
Andrew Lee, Assistant City Solicitor

In 1991 Newton Community Development Foundation (NCDF) purchased the former Warren Junior High School on Washington Street from the City for \$600,000. Subsequently in October of 1992, NCDF entered into a ground lease with the City for 65 years wherein it would operate and manage 59 apartment units in the former school building, 21 of which would be affordable apartments. The terms of the original lease required NCDF to provide the City with a 65 year term lease payment of \$1.5 million, payable in annual installments of \$75,000. The parties also agreed to a provision to defer payment on the annual rent if 50% of the property cash flow in a given year was less than the annual \$75,000 payment and any deferred rent would accrue at 8% simple interest. NCDF has paid all of the City's property taxes since acquiring the building but except for a negligible lease payment of \$3,997 never generated cash flow sufficient to make any further payments on the lease. At present, the outstanding principal rent due to the City is approximately \$1.4 million and the deferred interest is approximately \$2.4 million.

NCDF is looking to both refinance their current mortgage for needed capital improvements and to extend their current ground lease with the City (due to expire in 2056) for an additional 34 years to 2090.

As part of their request, NCDF has offered to provide the following:

1. Upon their refinance, NCDF would pay the City the principal rent balance of \$1.5 million.

2. NCDF would request that the City waive \$1.4 million of the interest amount owed and have NCDF pay a total of \$1 million to the City in equal annual installments of \$38,461 for 26 years, beginning in 2064.
3. In return for the City's forbearance, NCDF would agree to preserve the affordability of the current 21 units (including six where the 50% AMI affordability period has expired) in perpetuity and;
4. Agree to add affordability requirements to make another four (4) units affordable (at 80% AMI) in perpetuity for 25 units in total (42% of all units).

Please find attached draft language for the Special Act.

Please let me know if I can answer any questions related to this request.

AN ACT AUTHORIZING THE CITY OF NEWTON
TO LEASE THE WARREN JUNIOR HIGH SCHOOL

Be it enacted by the Senate and House of Representatives in General Court assembled,
and by the authority of the same, as follows:

Section 1. Notwithstanding the provisions of section 3 of chapter 40 of the General Laws or chapter 330 of the Acts of 1981 or of any other general or special law to the contrary, the city of Newton may lease the Warren Junior High School for a term of years not exceeding 99 years.

Section 2. Notwithstanding the provisions of chapter 30B of the general laws or of any other general law or special law to the contrary, the city of Newton may grant a lease extension to Warren House Associates Limited Partnership, the current lessee of the Warren Junior High School, without undertaking a procurement process

Section 3. This act shall take effect upon its passage.

CITY OF NEWTON

IN CITY COUNCIL

_____, 2023

ORDERED:

That City Council hereby requests and authorizes her Honor the Mayor to submit a home rule petition to the General Court seeking the adoption of special legislation as set out below:

SECTION 1. Notwithstanding chapter 132B of the General Laws or any other general or special law to the contrary, the City of Newton may by ordinance prohibit the application of second generation anti-coagulant rodenticides within the City of Newton, including application of such pesticides by licensed commercial applicators as defined in 333 C.M.R. 10.00.

SECTION 2. This act shall take effect upon its passage.

Under Suspension of Rules
Readings Waived and Approved

(SGD) CAROL MOORE
City Clerk

(SGD) RUTHANNE FULLER
Mayor



Ruthanne Fuller
Mayor

City of Newton, Massachusetts
Office of the Mayor

#155-23

Telephone
(617) 796-1100
Fax
(617) 796-1113
TDD/TTY
(617) 796-1089
Email
rfuller@newtonma.gov

April 24, 2023

Honorable City Council
Newton City Hall
1000 Commonwealth Avenue
Newton, MA 02459

Honorable City Councilors:

I respectfully submit a docket item to your Honorable Council requesting authorization to appropriate and expend the sum of \$140,000 from Acct # 5503R602-590001 B.A.A. Marathon to a Parks, Recreation & Culture Account to fund a "Heartbreak Hill" banner and playground improvements.

\$50,000 will be used for improvements to the Heartbreak Hill summit area for the installation of permanent support poles for the City's top of Heartbreak Hill marathon banner. The banner has been temporarily hung using trucks for the past two marathons and a permanent pole solution would be advantageous from staffing and aesthetic perspectives.

The second amount is for \$90,000 for playground improvements. The certified playground safety inspector in the Department of Parks, Recreation & Culture is conducting site reviews this spring. The playground locations and extent of each improvement will be determined by her findings. BAA Boston Marathon funds have traditionally been used for City playground improvements.

Please see attached a memo from Nicole Banks, Commissioner of Parks, Recreation & Culture.

Thank you for your consideration of this matter.

Sincerely,

Mayor Ruthanne Fuller

CITY CLERK
NEWTON, MA, 02459

2023 APR 24 PM 4:44

RECEIVED

Newton Parks, Recreation & Culture Department
246 Dudley Road, Newton, MA 02459
Office: (617) 796-1500
parks@newtonma.gov
Nicole Banks, Commissioner

#155-23



April 24, 2023

Re: Request for BAA Marathon funds to be appropriated for playground improvements and Heartbreak Hill improvements.

Dear Mayor Fuller:

I am writing to respectfully request that you docket an amount of \$140,000 with the Honorable City Council for two purposes. The first is for \$50,000 improvements to the Heartbreak Hill summit area for the installation of permanent support poles for the City's top of Heartbreak Hill marathon banner. The second amount is for \$90,000 for playground improvements at locations throughout the city. Our Department's certified playground safety inspector is conducting site reviews now. The playground locations and extent of each improvement will be based on her findings. Having these funds available promptly will allow us to implement repairs and improvements without delay.

Thank you for your consideration of this request.

Respectfully,

Nicole Banks, Commissioner, Parks, Recreation & Culture

4/24/2023
Date



Ruthanne Fuller
Mayor

City of Newton, Massachusetts
Department of Financial Planning & Analysis
1000 Commonwealth Avenue Newton, Massachusetts 02459

Telephone
(617) 796-1047

Email
prosenfield@newtonma.gov

www.newtonma.gov

Perry Rosenfield
Manager

MEMORANDUM

Date: June 15, 2023
To: Joshua Krintzman, Chair of Programs & Services
From: Perry Rosenfield, Manager of Financial Planning & Analysis
Cc: Maureen Lemieux, CFO & Jonathan Yeo, COO
Subject: Request for Actual Expenses for the 2023 Boston Marathon

President Albright requested information on the costs incurred by City Departments for the 2023 Boston Marathon.

City Departments do a lot to prepare for, host and clean-up after the Boston Marathon. Especially after the 2013 bombing, we work hard to provide a safe and joyous experience for thousands of runners and spectators on the longest stretch of the Marathon in any city or town.

In 2023, the direct overtime costs for the Marathon were:

Public Works:	\$ 45,011.88
Parks, Recreation & Culture:	\$ 9,988.00
Police:	\$ 32,599.51
Fire:	\$ 16,219.18
<i>Total</i>	<i>\$103,818.57</i>

In 2023, the Boston Athletic Association (BAA) compensated the City for costs associated with the Marathon with a payment of \$140,600. As part of the budget process, those funds are applied as revenue to next year’s General Fund.

Due to the pandemic, we had an unusual year with two Boston Marathons in one fiscal year. The funding in docket # 155-23 pertains to the BAA payment from the October 2021 Marathon. The City had only appropriated one BAA payment (April 2022) toward the FY2023 revenue budget, and therefore, has a surplus in that fund. Per the docket item, the \$140,000 request is for \$50,000 for the installation of permanent poles for a “Heartbreak Hill” banner as well as \$90,000 for playground improvements.